CHANGES IN MANAGEMENT OF KARO BIO AB
STOCKHOLM, August 17, 2011 - Karo Bio AB (publ) today announced that Jens Kristensen, Chief Medical Officer and Vice President Preclinical Development and Regulatory affairs, leaves his position.Acting President and CEO Per Bengtsson will temporarily assume management responsibility for clinical development and regulatory affairs until a new Chief Medical Officer has been recruited. The change in management will not affect the clinical development plan of eprotirome. For further information please contact:Göran Wessman, Chairman of the BoardCell: +46 708 161 450 Per Bengtsson,